ABSTRACT
OBJECTIVES: To describe the current real-world treatment landscape, sequence of therapies, and outcomes in patients with prostate cancer (PC). METHODS: A retrospective cohort study for PC patients diagnosed at King Abdullah Medical City Cancer Center in Makkah, Saudi Arabia, between January 2011 and December 2021. Data extracted from electronic medical records. RESULTS: A total of 282 patients with PC, with a mean age of 70 years and body mass index of 27. Among them, 274 (99%) had no family history of cancer, while 164 (58%) had hypertension and 125 (44%) had diabetes mellitus. Adenocarcinoma was the most common histology, found in 275 (97%) patients, with 99 (35%) having a Gleason score of 9. Notably, 184 (65%) patients presented with metastatic disease, and 147 (52%) with bone metastasis. While 198 (70%) patients underwent surgery, 184 (65%) did not receive radiotherapy. The most common first-line metastatic therapy was abiraterone in 23 (8%) patients, followed by enzalutamide in 7 (2.5%). During the study period, 167 (59%) patients survived, with an average treatment duration of 2.5 years. CONCLUSION: This study provides insights into real-world treatment patterns and clinical outcomes in patients with PC. The findings of this study highlight the importance of adhering to treatment standards and making informed clinical decisions.
Subject(s)
Prostatic Neoplasms , Humans , Male , Prostatic Neoplasms/therapy , Prostatic Neoplasms/pathology , Saudi Arabia/epidemiology , Retrospective Studies , Aged , Middle Aged , Treatment Outcome , Phenylthiohydantoin/therapeutic use , Phenylthiohydantoin/analogs & derivatives , Nitriles/therapeutic use , Neoplasm Grading , Adenocarcinoma/therapy , Adenocarcinoma/pathology , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Androstenes/therapeutic use , Prostatectomy , Cohort Studies , Aged, 80 and over , BenzamidesABSTRACT
Background and aim Globally, there is a discrepancy in whether terminal cancer patients are early referred to palliative care service (PCS) or not. A late referral can lead to a delay in treating and palliating those patients in need. The aim of this study is to investigate the referral time patterns of advanced cancer patients to PCS in Princess Noorah Oncology Center (PNOC) at King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia. In addition, this study evaluates the factors that influence referral time to the palliative care unit (PCU), along with the overall survival rate. Methods This was a retrospective cross-sectional study (chart review) conducted at the inpatient unit in PNOC and included all patients referred to PCS between January 1st, 2016, and December 31, 2016. In total, 153 patients met the inclusion criteria, and their data were collected and analyzed. Results The median length of stay (LOS) was five days (95% CI: 3.85-6.15). Among the 153 patients, 22 (14.4%) died within 24 hours of enrollment to PCU. Patients who were referred to the PCU with non-metastasis disease had a median LOS of nine days, which is significantly longer than the median LOS in patients with metastatic disease (95% CI: 0.35-0.82, p=0.004), which indicates that they referred relatively earlier to PCU. The hazard ratio for death in patients with non-metastatic cancer stage was 0.54 (95% CI: 0.35-0.82, p=0.004). Conclusion Referral of advanced cancer patients to palliative care services occurs late in their disease course in our institution, like other institutions, with variation in LOS, which shorten their stay at palliative, as well as, affects their quality of life (QOL) and ability to plan or make a decision regarding their care. Education of the public and, most importantly, the medical community is needed.
